Citius Oncology, Inc. CTOR Convertible Preferred Stock Authorized Shares
Convertible Preferred Stock Authorized Shares at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s convertible preferred stock authorized shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s convertible preferred stock authorized shares?
- Citius Oncology, Inc. (CTOR) reported convertible preferred stock authorized shares of 10M in Q1 2026.
- How has Citius Oncology, Inc.'s convertible preferred stock authorized shares changed year-over-year?
- Citius Oncology, Inc.'s convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
- What is the long-term trend for Citius Oncology, Inc.'s convertible preferred stock authorized shares?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s convertible preferred stock authorized shares has grown at a 115.4% compound annual growth rate (CAGR), from 1M to 10M.
- What does convertible preferred stock authorized shares mean?
- Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.